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Purpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular 
surface disease index (OSDI) in glaucoma patients after switching therapy from latanoprost 
with 0.02% benzalkonium chloride (BAK) to travoprost with sofZia™.
Methods: Prospective consecutive case series evaluating patients before and 8 weeks after 
switching from latanoprost with BAK to travoprost with sofZia™ in patients with baseline 
TBUT less than 6 seconds.
Results: Forty eyes of 20 consecutive patients using latanoprost with BAK were switched to 
travoprost with sofZia™. Mean TBUT prior to starting travoprost was 2.02 ± 0.71 seconds and 
increased to 6.34 ± 1.31 seconds 8 weeks after the switch (p  0.001). Mean inferior corneal 
staining scores decreased from 2.40 ± 0.87 to 1.38 ± 0.59 (p  0.001). Mean OSDI scores 
decreased from 26.31 ± 8.25 to 16.56 ± 6.19 (p  0.001).
Discussion: This report focuses on the status of the ocular surface, as documented by TBUT, 
corneal staining and OSDI, in patients switched from latanoprost with BAK to travoprost 
without BAK. The switch resulted in a statistically signiﬁ  cant increase in TBUT and decreases 
in corneal staining and OSDI in patients with low baseline TBUT values.
Conclusion: BAK, a common preservative for glaucoma drops, may increase OSD by dis-
rupting the tear ﬁ  lm and increasing conjunctival inﬂ  ammation. In this study, a change from 
a BAK-preserved prostaglandin analog (PGA) to a non-BAK-preserved PGA resulted in a 
measurable improvement of TBUT, corneal staining and OSDI. Further studies are needed to 
better understand the impact of BAK-preserved medications on the ocular surface.
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The US Food and Drug Administration requires manufacturers of multi-dose topical 
ophthalmic medications to include preservative systems against microbial contamina-
tion. Clinicians have long understood that, along with the beneﬁ  ts of safety in pro-
longed usage and decreased potential of ocular infection, there are proven deleterious 
side effects with chronic exposure to some preservatives.1 These effects have been 
demonstrated in animals and humans with both in vitro and in vivo models.2–5 Studies 
have also demonstrated that when comparing topical medications with preservatives 
and their non-preserved counterpart, there is less ocular toxicity, suggesting a direct 
correlation with the presence of preservative and damage to the ocular surface.5–7
One of the more common preservatives used today is benzalkonium chloride 
(BAK).8 BAK is a quaternary ammonium compound whose antimicrobial activity 
arises from its ability to disrupt cell membranes and potentiate cell death. Along with 
its antimicrobial activity, BAK is toxic to the corneal epithelium as well as conjunctival 
epithelium and stroma.4,9–16 These changes appear to be both dose- and time-dependent. 
These toxic side effects come to the forefront in the care of glaucoma patients due to 
the cumulative amount of BAK that can be introduced through a multiple drop regimen 
lasting decades. Alternative preservatives have been introduced including oxidizing Clinical Ophthalmology 2009:3 292
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agents, such as sofZia™ (Alcon Laboratories, Inc., Fort 
Worth, Texas, USA) that contains borate, zinc and sorbitol. 
Oxidizing agents may lead to less cell damage than detergent 
preservatives such as BAK.
This study focuses on the effects of topical antiglaucoma 
medications in patients with pre-existing ocular surface 
disease. We aim to quantify changes in tear break-up time 
(TBUT), corneal staining and the ocular surface disease index 
(OSDI) after switching from latanoprost with 0.02% BAK 
to travoprost with sofZia™.
Materials and methods
This was a prospective, open label, single-center study 
involving 40 eyes of twenty consecutive patients presenting 
to a tertiary care glaucoma practice. The study design was 
approved by the University of Colorado Internal Review 
Board. Each patient had been taking latanoprost monotherapy 
for at least 12 months prior to enrollment. All patients had a 
baseline tear break-up time (TBUT) of less than 6 seconds. 
Patients were instructed to avoid adding other topical drops 
during the study period. Baseline measurements of TBUT, 
inferior corneal staining and ocular surface disease index 
(OSDI) were obtained for each enrollee between 7 and 10 AM 
and in the same examination room at each visit.
TBUT was obtained by placing 5 μL of 2% preservative-
free sodium ﬂ  uorescein (NaFl) to the inferior fornix using 
a ﬁ  xed volume micropipette. To thoroughly mix the NaFl 
with the tear ﬁ  lm, the subject was instructed to blink three 
times. The slit lamp was set at a magniﬁ  cation of 16 × using 
cobalt blue illumination and a stopwatch was used to time 
the occurrence of the ﬁ  rst break in the ﬂ  uorescein stained tear 
ﬁ  lm (Figure 1A and B). The timer was started immediately 
after the last blink and stopped at the ﬁ  rst break in ﬂ  uorescein. 
This was measured three consecutive times and an average 
of these measurements was used to calculate the ﬁ  nal TBUT. 
At the 8-week follow-up, each TBUT was obtained by the 
same observer (MYK) using the same method as described 
above. Inferior corneal staining was measured on a scale 
of 0 to 4 (0 = none, 1 = mild, 2 = moderate, 3 = severe, 
4 = conﬂ  uent) at baseline and ﬁ  nal follow-up visits. The 
ocular surface disease index questionnaire was given to the 
participants at both the initial visit as well as the eight-week 
follow-up. We used Student’s t-test to compare data between 
the two visits.
Results
All 20 patients (40 eyes) enrolled in the study who 
completed the final evaluation were included in data 
analysis (Figure 2A and B, Table 1). One patient did not 
return at the 8-week mark and was excluded from analysis. 
The patients ranged in age from 42 to 78 years, 16 were 
Caucasian and 4 African American, 12 were male and all 
were diagnosed with open angle glaucoma. Prior to starting 
travoprost, the mean TBUT was 2.02 ± 0.71 seconds for 
the 40 eyes studied. This increased to 6.34 ± 1.31 seconds 
8 weeks after the switch (p  0.001). Inferior corneal 
A) B)
Figure 1 A) Tear break-up time (TBUT) showing breaks in the ﬂ  uorescein after 1 second; B) the same patient on follow-up visit with TBUT (white arrow) ﬁ  rst appearing at 
7 seconds.Clinical Ophthalmology 2009:3 293
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staining decreased from 2.40 ± 0.87 to 1.38 ± 0.59 
(p  0.001). The OSDI initially measured 26.31 ± 8.25 
which is within the moderate category. Eight weeks after 
switching to travoprost, the OSDI fell into the mild cat-
egory: 16.56 ± 6.19 (p  0.001) in this same population of 
20 patients. There was no statistically signiﬁ  cant difference 
in intraocular pressure (IOP) levels at baseline (14.05 ± 2.78 
mmHg) and after the switch to travoprost with sofZia™ 
(13.95 ± 3.04, p = 0.88).
Discussion
BAK is the most commonly used ophthalmic preservative. 
Multiple studies have delineated the deleterious effects 
of BAK on conjunctival epithelium, corneal epithelium 
and corneal stroma.4,9–20 The microscopic changes seen in 
patients taking BAK include an increase of pro-inﬂ  ammatory 
cytokines, lymphocyte inﬁ  ltration, ﬁ  broblast proliferation, 
corneal microvilli loss and goblet cell loss in the conjunctival 
epithelium. In addition, these ocular surface changes may 
decrease the success rate of glaucoma surgery.21 It is also 
not surprising that changes to the tear ﬁ  lm and increase in 
inﬂ  ammation result in a worsening of symptoms in patients 
with preexisting dry eye who are also treated with preserved 
topical glaucoma drops.14–16
Yee et al22 found that there was a marked reduction in tox-
icity when exposing immortalized human corneal epithelial 
cells to travoprost with sofZia™ compared to latanoprost with 
BAK. Kahook et al19 described similar ﬁ  ndings in both cor-
neal and conjunctival changes in New Zealand white rabbits. 
Their results concluded that an increase in inﬂ  ammation, as 
measured by lymphocytic inﬁ  ltration, was found in tissue 
exposed to latanoprost with BAK as compared to travoprost 
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Figure 2 A) Mean tear break-up time on latanoprost and after switch to travoprost without BAK; B) Mean ocular surface disease index on latanoprost and after switch to 
travoprost without BAK.
Abbreviations: BAK, benzalkonium chloride; OSDI, ocular surface disease index.Clinical Ophthalmology 2009:3 294
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with SofZia. Also, corneal epithelial damage was statistically 
higher in the latanoprost with BAK group compared to the 
travoprost with sofZia™ group.
The ocular surface disease index, was reported by 
Schiffman et al23 as both a valid and reliable means to quan-
tify dry eye syndrome. Using this questionnaire, our study 
found a statistically signiﬁ  cant improvement of OSDI in 
patients switched from latanoprost with BAK to travoprost 
with sofZia™. Patients who have less ocular irritation may be 
more likely to be adherent to their medication regimen. This 
could lead to more effective lowering of IOP and resultant 
decrease of glaucomatous vision loss. We also found a statis-
tically signiﬁ  cant improvement in tear break-up time (TBUT) 
after patients were switched to travoprost with sofZia™. For 
patients with an already reduced TBUT, this change appears 
to correlate to a signiﬁ  cant improvement in dry eye symptoms 
as reﬂ  ected by the improvement in OSDI.
While maintaining antimicrobial activity, studies have 
shown sofZia™ to have less deleterious effects than BAK on 
ocular epithelium in both in vitro and in vivo studies.19,22,24 In 
addition, when comparing travoprost with BAK (Travatan®; 
Alcon Laboratories, Inc., Fort Worth, Texas, USA) to travo-
prost with sofZia™ (Travatan Z®; Alcon Laboratories, Inc., Fort 
Worth, Texas, USA), the IOP-lowering efﬁ  cacy was found to be 
identical.25 Thus, it appears that BAK is not required for either 
safety or efﬁ  cacy of travoprost as an ocular hypotensive agent.
Although the results of both the OSDI and TBUT show 
a statistically significant improvement when switching 
from latanoprost with BAK to travoprost with sofZia™, we 
focused our study only on patients with measurably decreased 
TBUT at baseline, thus limiting the generalization of our 
results. Also, the number of patients enrolled is low and we 
included both eyes of each patient in our analysis. Finally, 
all participants lived in the low humidity environment of 
Denver or surrounding suburbs making generalizations to 
other geographic areas difﬁ  cult to make.
The results of this study suggest that a change from a 
BAK-preserved prostaglandin analog to a prostaglandin 
analog preserved with sofZia™ could improve TBUT, 
corneal staining and OSDI score while maintaining 
similar IOP-lowering efﬁ  cacy. These ﬁ  ndings cannot 
be extrapolated to other BAK-preserved medications 
owing to the limited nature of this open-label pilot study. 
Further prospective and randomized studies are needed 
to better understand and conﬁ  rm the effect of BAK on 
the ocular surface of glaucoma patients and to quantify 
possible effects on patient compliance and overall disease 
progression.
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